Details
Title
Metabolomic adaptations and correlates of survival to immune checkpoint blockade
Author
Li, Haoxin 1 ; Bullock, Kevin 2 ; Carino Gurjao 3 ; Braun, David 4 ; Shukla, Sachet A 4 ; Bossé, Dominick 4
; Lalani, Aly-Khan A 4
; Gopal, Shuba 2 ; Jin, Chelsea 5 ; Horak, Christine 5 ; Wind-Rotolo, Megan 5 ; Signoretti, Sabina 4 ; McDermott, David F 6 ; Freeman, Gordon J 4
; Van Allen, Eliezer M 7
; Schreiber, Stuart L 8 ; Hodi, F Stephen 9 ; Sellers, William R 3
; Garraway, Levi A 7 ; Clish, Clary B 2
; Choueiri, Toni K 9
; Giannakis, Marios 7
1 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA; Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA, USA
2 Broad Institute of MIT and Harvard, Cambridge, MA, USA
3 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA
4 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
5 Bristol-Myers Squibb, Princeton, NJ, USA
6 Beth Israel Deaconess Medical Center, Boston, MA, USA
7 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA; Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
8 Broad Institute of MIT and Harvard, Cambridge, MA, USA; Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA, USA
9 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
; Lalani, Aly-Khan A 4
; Gopal, Shuba 2 ; Jin, Chelsea 5 ; Horak, Christine 5 ; Wind-Rotolo, Megan 5 ; Signoretti, Sabina 4 ; McDermott, David F 6 ; Freeman, Gordon J 4
; Van Allen, Eliezer M 7
; Schreiber, Stuart L 8 ; Hodi, F Stephen 9 ; Sellers, William R 3
; Garraway, Levi A 7 ; Clish, Clary B 2
; Choueiri, Toni K 9
; Giannakis, Marios 7 1 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA; Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA, USA
2 Broad Institute of MIT and Harvard, Cambridge, MA, USA
3 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA
4 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
5 Bristol-Myers Squibb, Princeton, NJ, USA
6 Beth Israel Deaconess Medical Center, Boston, MA, USA
7 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA; Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
8 Broad Institute of MIT and Harvard, Cambridge, MA, USA; Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA, USA
9 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
Pages
1-6
Publication year
2019
Publication date
Sep 2019
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2297119097
Copyright
© 2019. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.